ipamorelin selective growth hormone releasing peptide CJC-1295 (Mod GRF 1-29) & & GHRP-2 - 9MG Side effects of Ipamorelin_Chemicalbook

In practice contexts, tolerance is generally reported as good when product quality is reliable

10.1186/1476-5918-8-1 101 FjellA

The 2025 Frontiers in Aging clinical review (Frontiers in Aging 2025) summarises the documented short-term adverse effects in adult populations: peripheral oedema and fluid retention are common at initiation, carpal tunnel syndrome occurs in a meaningful proportion of users, hyperglycaemia and insulin resistance can emerge because GH is physiologically counter-regulatory to insulin, and gynaecomastia has been reported, particularly at higher doses

CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1

Local Reactions: Redness, swelling, itching, or pain at the subcutaneous injection site

You can learn more about this approach in Why Bioavailability Matters